This week's View summarizes two recent publications, one a trial showing that a 5-day course of remdesivir was superior to standard therapy at improving clinical status among patients with moderate coronavirus disease 2019 infection, and the other a prespecified secondary analysis within the PARAGON-HF trial looking at the impact of angiotensin-neprilysin inhibition on renal events among patients with heart failure with preserved ejection fraction.

Subscribe on Apple Podcasts | Subscribe on Google Play

Clinical Topics: COVID-19 Hub, Diabetes and Cardiometabolic Disease, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Chronic Heart Failure, Heart Failure and Cardiac Biomarkers

Keywords: EaglesEyeView, Coronavirus, Coronavirus Infections, severe acute respiratory syndrome coronavirus 2, COVID-19, ACC COVID-19 Podcast, Primary Prevention, Secondary Prevention, Angiotensins, Blood Pressure, Cardio-Renal Syndrome, Diuretics, Extracorporeal Membrane Oxygenation, Geriatrics, Glomerular Filtration Rate, Heart Failure, Hyperkalemia, Hypertrophy, Left Ventricular, Kidney Diseases, Metabolic Syndrome, Natriuretic Peptides, Neprilysin, Noninvasive Ventilation, Oxygen, Pneumonia, remdesivir, Renal Insufficiency, Respiration, Artificial, Stroke Volume, Ventilation

< Back to Listings